| Literature DB >> 35235843 |
Muriel D van Kampen1, Leonie H A M Kuipers-De Wilt1, Mariëlle L van Egmond1, Petra Reinders-Blankert1, Ewald T J van den Bremer1, Guanbo Wang2, Albert J R Heck2, Paul W H I Parren3, Frank J Beurskens1, Janine Schuurman1, Rob N de Jong4.
Abstract
The hexamerization of natural, human IgG antibodies after cell surface antigen binding can induce activation of the classical complement pathway. Mutations stimulating Fc domain-mediated hexamerization can potentiate complement activation and induce the clustering of cell surface receptors, a finding that was applied to different clinically investigated antibody therapeutics. Here, we biophysically characterized how increased self-association of IgG1 antibody variants with different hexamerization propensity may impact their developability, rather than functional properties. Self-Interaction Chromatography, Dynamic Light Scattering and PEG-induced precipitation showed that IgG variant self-association at neutral pH increased in the order wild type (WT) < E430G < E345K < E345R < E430G-E345R-S440Y, consistent with functional activity. Self-association was strongly pH-dependent, and single point mutants were fully monomeric at pH 5. Differential Scanning Calorimetry and Fluorimetry showed that mutation E430G decreased conformational stability. Interestingly, heat-induced unfolding facilitated by mutation E430G was reversible at 60°C, while a solvent-exposed hydrophobic mutation caused irreversible aggregation. Remarkably, neither increased dynamic self-association propensity at neutral pH nor decreased conformational stability substantially affected the stability of concentrated variants E430G or E345K during storage for two years at 2-8°C. We discuss how these findings may inform the design and development of IgG-based therapeutics.Entities:
Keywords: Biophysical properties; Conformational and Colloidal stability; Developability; HexaBody; Hexamerization; Reversible self-association
Mesh:
Substances:
Year: 2022 PMID: 35235843 DOI: 10.1016/j.xphs.2022.02.016
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.784